4-Hydroxy atorvastatin (hemicalcium)

4-Hydroxy atorvastatin hemicalcium is a metabolite of Atorvastatin (HY-B0589) . Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin[1][2].

Product Specifications

CAS Number

[265989-44-4]

UNSPSC

12352005

Hazard Statement

H302

Target

Drug Metabolite; HMG-CoA Reductase (HMGCR)

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Purity

96.19

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@@H](C[C@@H](O)CC(O)=O)CCN1C(C(C=C2)=CC=C2F)=C(C3=CC=CC=C3)C(C(NC(C=C4)=CC=C4O)=O)=C1C(C)C.[1/2].[Ca]

Molecular Formula

C33H35FN2O6.1/2Ca

Molecular Weight

594.68

Precautions

H302

References & Citations

[1]van Dam M, et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart. 2002;88 (3) :234-238. |[2]Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care. 2001;24 (8) :1335-1341.